Jazz Pharmaceuticals PLC Form 4 insider transactions

Jazz Pharmaceuticals plc's EVP, Global Head of R&D & CMO, Robert Iannone, increased his direct beneficial ownership of ordinary shares following the vesting of performance awards and an Employee Stock Purchase Plan acquisition.

Jazz Pharmaceuticals plc's President & CEO, Renee D Gala, reported the vesting of performance share awards and subsequent tax-related share withholding.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd increased his direct beneficial ownership of ordinary shares following the vesting of performance awards and subsequent tax-related share withholding.

Jazz Pharmaceuticals plc Director Patrick G. Enright transferred 5,000 ordinary shares to a former spouse as part of a marital asset division.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 2,238 ordinary shares for a weighted average price of $169.511 per share.

Jazz Pharmaceuticals' President & CEO, Renee D Gala, reported a disposition of 80 ordinary shares for tax purposes and an acquisition of 71 shares via an employee stock plan.

Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, reported exercising stock options and selling ordinary shares on December 5, 2025.

Kenneth W. O'Keefe, a director at Jazz Pharmaceuticals plc, sold 603 ordinary shares to cover tax liabilities from vested restricted stock units.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd exercised stock options and subsequently sold a portion of his ordinary shares on November 26, 2025.

Jazz Pharmaceuticals plc Director Heather McSharry exercised non-qualified stock options and subsequently sold 3,415 ordinary shares.

Jazz Pharmaceuticals' SVP of Technical Operations, Mary Elizabeth Henderson, sold 1,331 ordinary shares to cover tax liabilities from vested restricted stock units.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd reported the sale of 18,000 ordinary shares and the acquisition of 2,506 restricted stock units.

Jazz Pharmaceuticals' SVP and Chief Accounting Officer, Patricia Carr, reported exercising stock options and selling shares, including those from an employee stock purchase plan.

Jazz Pharmaceuticals plc Director Rick E. Winningham sold 5,500 ordinary shares at $180.8597 per share in a pre-planned transaction.

Jazz Pharmaceuticals' EVP, Global Head of R&D & CMO, Robert Iannone, sold 7,159 ordinary shares for $168.26 each as part of a pre-arranged trading plan.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd sold 5,500 ordinary shares for approximately $730,000 under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals director Bruce C. Cozadd disposed of 15,647 ordinary shares to cover tax obligations related to restricted stock unit vesting.

Jazz Pharmaceuticals plc Director Bruce C. Cozadd sold 6,000 ordinary shares in pre-planned transactions on September 2, 2025.

Jazz Pharmaceuticals director Kenneth W. O'Keefe reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Jazz Pharmaceuticals plc director Jennifer E. Cook received a grant of 3,507 restricted stock units and sold 1,805 shares to cover tax obligations from a prior RSU vesting.

A Jazz Pharmaceuticals director acquired restricted stock units and sold shares to cover tax obligations from a prior vesting event.

A Jazz Pharmaceuticals director acquired new restricted stock units and sold shares to cover tax obligations from prior vesting.

A Jazz Pharmaceuticals director reported acquiring restricted stock units and selling shares to cover tax obligations from prior equity awards.

A Jazz Pharmaceuticals director acquired new restricted stock units and sold shares to cover tax obligations from a prior vesting.

Jazz Pharmaceuticals plc Director Anne O'Riordan reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Jazz Pharmaceuticals plc Director Norbert G. Riedel reported the grant of restricted stock units and a subsequent sale of shares to cover tax obligations.

A Jazz Pharmaceuticals director reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

A Jazz Pharmaceuticals plc director reported acquiring restricted stock units and selling shares to cover tax obligations.

Jazz Pharmaceuticals plc Director Seamus Mulligan reported the acquisition of 3,507 restricted stock units.

Jazz Pharmaceuticals plc's President and CEO, Renee D. Gala, reported the acquisition of 18,808 ordinary shares through a restricted stock unit grant and 166 shares via an employee stock purchase plan.